The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Phivida Enters into Supply Agreement with Artelo Biosciences
Dec. 29, 2017 08:03AM PST
Cannabis Investing NewsPhivida Holdings Inc. (“Phivida” – “C.VIDA” – “US.PHVAF”) is pleased to report that Phivida Organics Inc., a wholly owned US operating subsidiary of Phivida, has entered into a product formulation and wholesale supply agreement with Artelo Biosciences, Inc. (“Artelo”, OTCBB: ARTL).
Phivida Holdings Inc. (“Phivida” – CSE:VIDA – “US.PHVAF”) is pleased to report that Phivida Organics Inc., a wholly owned US operating subsidiary of Phivida, has entered into a product formulation and wholesale supply agreement with Artelo Biosciences, Inc. (“Artelo”, OTCBB: ARTL). The purpose of this supply and formulation agreement is to provide pharmaceutical grade cannabidiol (CBD) isolate for research at a prestigious University based in the United Kingdom, sponsored by Artelo.
The Artelo supply agreement names Phivida as a qualified and preferred supplier for cGMP certified active pharmaceutical ingredient (API) grade hemp oil derived CBD isolate for Artelo funded studies. Key terms include mandatory prequalification testing of every batch and lot, verified by a third-party ISO/IEC 17025 certified and cannabinoid testing accredited laboratory using cutting edge High-Performance Liquid Chromatography (HPLC) analysis technology. Each batch and lot test must produce a Certificate of Analysis (COA) which thoroughly validates product quality (i.e. phytocannabinoids potency and terpenes profile) and safety (i.e. microbiological, residual solvents, pesticides and heavy metal analysis) characteristics.
In addition to pharmaceutical grade isolates, Phivida provides access to a range of premium CBD bulk products derived from certified organic hemp. As a mandatory internal QA/QC standard, Phivida hemp derived products processed at cGMP certified processing facilities using cutting edge super critical Co2 extraction processing technologies. Beyond isolates, wholesale products include; hot and cold filtered full spectrum CBD Hemp Oil with a rich profile of phytocannabinoids and terpenes (while maintaining <0.3% THC), as well as its flagship nanoencapsulated Hemp Oil extracts and isolates, for enhanced delivery and uptake potential as well as water solubility (used in Phivida branded clinical and consumer beverage products).
“Artelo places a premium on quality, compliance, consistency and reliability. When we looked for potential suppliers, we were delighted Phivida had already implemented key professional production and testing standards which were critical to Artelo when identifying a partner as an API supplier,” stated Gregory Gorgas, Chief Executive Officer of Artelo.
Phivida President and CEO, John Belfontaine stated; “Phivida is pleased to provide access to API grade CBD for Artelo’s sponsored research initiatives. Phivida management actively supports the scientific research of the safety and efficacy of phytocannabinoids on a wide range of diseases and medical conditions. We value our long term strategic relationships with biopharmaceutical companies like Artelo, and look forward to future opportunities to promote research on cannabinoid pharmacology, participate as a key contributor of API grade CBD, and meaningfully contribute to generating evidence of its potential to improve human health”.
About Phivida
Phivida [“fiii-vee-daa”] is a publicly traded company listed on the Canadian Securities Exchange under the ticker symbol “VIDA”. Phivida is a premiere brand of cannabidiol (“CBD“) infused functional foods, beverages and clinical health products, poised for global distribution. Using nanoencapsulation technology, Phivida converts lipid based cannabinoids into water soluble delivery format, enhancing bioavailability, and timed released within the body. Phivida’s nanoencapsulated CBD is infused into CBD beverages, foods and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health conditions, from chronic pain to terminal diseases. Phivida Enhanced Inc. (a wholly owned subsidiary of Phivida Holdings Inc.) is the clinical division of Phivida responsible for the formulation, manufacturing and distribution of the professional line clinical products under the brand name Vida+. These clinical grade CBD products include sublingual’s, hard capsules and other full spectrum CBD-hemp oil extract infused nutraceuticals and natural health products. The Vida+ label is a professional line of products clinical grade for higher potency and are third party laboratory tested for cannabinoid potency, terpenes, residual solvents, bacteria and pesticides. Celebrating; Health and Wellness, In Harmony™, Phivida’s mission is to lead the alternative health care sector as the benchmark quality standard in premium cannabinoid infused foods, beverages and clinical products, with a dedication to research and education while investing back into the communities that we so proudly serve.
SOURCE Phivida Holdings Inc.
For further information: on Phivida visit www.phivida.com or: Website www.phivida.com; Toll free +1 (844) 744-6646 (ext. #2); Email IR@phivida.com; Twitter https://twitter.com/Phivida; Facebook https://www.facebook.com/phivida; YouTube https://www.youtube.com/watch?v=YqvHSMbhKwQ&t=7s
Click here to connect with Phivida Holdings Inc (CSE:VIDA) for an Investor Presentation.
In addition to pharmaceutical grade isolates, Phivida provides access to a range of premium CBD bulk products derived from certified organic hemp. As a mandatory internal QA/QC standard, Phivida hemp derived products processed at cGMP certified processing facilities using cutting edge super critical Co2 extraction processing technologies. Beyond isolates, wholesale products include; hot and cold filtered full spectrum CBD Hemp Oil with a rich profile of phytocannabinoids and terpenes (while maintaining <0.3% THC), as well as its flagship nanoencapsulated Hemp Oil extracts and isolates, for enhanced delivery and uptake potential as well as water solubility (used in Phivida branded clinical and consumer beverage products).
“Artelo places a premium on quality, compliance, consistency and reliability. When we looked for potential suppliers, we were delighted Phivida had already implemented key professional production and testing standards which were critical to Artelo when identifying a partner as an API supplier,” stated Gregory Gorgas, Chief Executive Officer of Artelo.
Phivida President and CEO, John Belfontaine stated; “Phivida is pleased to provide access to API grade CBD for Artelo’s sponsored research initiatives. Phivida management actively supports the scientific research of the safety and efficacy of phytocannabinoids on a wide range of diseases and medical conditions. We value our long term strategic relationships with biopharmaceutical companies like Artelo, and look forward to future opportunities to promote research on cannabinoid pharmacology, participate as a key contributor of API grade CBD, and meaningfully contribute to generating evidence of its potential to improve human health”.
About Phivida
Phivida [“fiii-vee-daa”] is a publicly traded company listed on the Canadian Securities Exchange under the ticker symbol “VIDA”. Phivida is a premiere brand of cannabidiol (“CBD“) infused functional foods, beverages and clinical health products, poised for global distribution. Using nanoencapsulation technology, Phivida converts lipid based cannabinoids into water soluble delivery format, enhancing bioavailability, and timed released within the body. Phivida’s nanoencapsulated CBD is infused into CBD beverages, foods and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health conditions, from chronic pain to terminal diseases. Phivida Enhanced Inc. (a wholly owned subsidiary of Phivida Holdings Inc.) is the clinical division of Phivida responsible for the formulation, manufacturing and distribution of the professional line clinical products under the brand name Vida+. These clinical grade CBD products include sublingual’s, hard capsules and other full spectrum CBD-hemp oil extract infused nutraceuticals and natural health products. The Vida+ label is a professional line of products clinical grade for higher potency and are third party laboratory tested for cannabinoid potency, terpenes, residual solvents, bacteria and pesticides. Celebrating; Health and Wellness, In Harmony™, Phivida’s mission is to lead the alternative health care sector as the benchmark quality standard in premium cannabinoid infused foods, beverages and clinical products, with a dedication to research and education while investing back into the communities that we so proudly serve.
SOURCE Phivida Holdings Inc.
For further information: on Phivida visit www.phivida.com or: Website www.phivida.com; Toll free +1 (844) 744-6646 (ext. #2); Email IR@phivida.com; Twitter https://twitter.com/Phivida; Facebook https://www.facebook.com/phivida; YouTube https://www.youtube.com/watch?v=YqvHSMbhKwQ&t=7s
Click here to connect with Phivida Holdings Inc (CSE:VIDA) for an Investor Presentation.
Source: www.newswire.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.